CTN-0002: Buprenorphine/Naloxone versus Clonidine for Outpatient Opiate Detoxification
Walter Ling, MD
Integrated Substance Abuse Programs
University of California Los Angeles
For decades clinicians, have been frustrated by the inability to successfully detoxify opiate addicted patients because opiate-based detoxification, one of the most effective means to achieving that goal, has been unavailable outside the very restrictive confines of narcotic treatment programs. Bup/Nx shows promise as an effective aid for opiate detoxification; however, little data have been generated for the shorter-term use of Bup/Nx for this indication. Because the diversity of clinics in the CTN provides an unparalleled opportunity to conduct such a clinical endeavor, the utility of buprenorphine/naloxone in short term (13 day) detoxification versus clonidine in an outpatient setting was tested in the CTN.
A total of 46 of the 157 (29%) outpatients assigned to Bup/Nx condition achieved the treatment success criterion, compared to 4 of the 74 (5%) assigned to clonidine. The study supports the benefits of Bup/Nx for opioid detoxification in outpatient treatment programs and illustrated important ways in which clinical research can be conducted in community treatment programs.
Primary Outcomes Article: Ling W, et al. A Multi-Center Randomized Trial of Buprenorphine-Naloxone versus Clonidine for Opioid Detoxification: Findings for the National Institute on Drug Abuse Clinical Trials Network. Addiction 2005;100:1090-1110. [get article]
- CTN-0002 Study Protocol
- Publications in the Library about CTN-0002
- Study data from NIDA Data Share
- Blending Team Product: Short Term Opioid Withdrawal Using Buprenorphine
- Blending Team Product: Buprenorphine Suite
- ClinicalTrials.gov (NCT00032968)
- NIDA protocol page
All Participating Nodes: